Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Putting It All Together: The Biologic Zoo
Description
The presentation revolves around effectively managing psoriasis treatment by discussing various biologic therapies in a systematic manner. The speaker emphasizes the importance of not getting lost in the details but rather focusing on overarching concepts when conversing with patients about their treatment options. It outlines three primary treatment methods: topical, phototherapy, and systemic, delving into the diverse biologics available and their ease of study, driven primarily by the straightforward pathophysiology of psoriasis. The importance of patient involvement in treatment decisions is highlighted, acknowledging that preferences and circumstances influence choices. The presentation categorizes biologics into three classes: anti-TNF therapy, anti-IL-23 therapy, and anti-IL-17 therapy, advising practitioners to consider the efficacy and safety profiles of each. The speaker presents various data illustrating drug efficacy and safety, supporting the notion that while there may be minimal differences between treatments, individual patient responses can vary. Ultimately, the talk encourages a comprehensive understanding of treatment options, stressing systematic thinking to better assist patients while navigating the complexities of treatment decisions amidst varying patient needs and preferences.
View moreConclusions
- There is a wide array of treatment options for psoriasis, which can be tailored to individual patient needs.
- A systematic approach to treatment selection enhances patient care and ensures that choices align with the patient's preferences and circumstances.
- Biologics have become increasingly available due to the straightforward pathophysiology of psoriasis and their predictable outcomes compared to small molecules.
- Both IL-17 and IL-23 inhibitors are effective in treating psoriasis, but they have different mechanisms and side effects, making patient-specific factors important in selection.
- Understanding the complexity of psoriasis treatment is crucial, particularly when considering comorbid conditions like psoriatic arthritis, as they can influence treatment choices.
- The safety profiles and long-term efficacy of available biologics vary, with ongoing evaluation of their impact on serious infections and other side effects necessary for informed patient decisions.
- Biosimilars provide a cost-effective alternative to existing biologic therapies, significantly impacting overall treatment expenditure in dermatology.
- Hawkes JE, et al. J Allergy Clin Immunol. 2017;140:645-653
- Ruggiero A, et al. Psoriasis (Auckl). 2022;12:127-137.
- Reich K, et al. Lancet 2019;
- Blauvelt A, et al. Br. J. Dermatol. 2020
- Apol E, et al. EADV 2019, P1695
- Singla S. Lancet Rheum. 2023
- Papp K, et al. J Drugs Dermatol 2015;14:706-714
- Griffiths C, et al. EADV 2020, P0372
- van der Kerkhof P, et al. J Am Acad Dermatol 2016;75:83-98
- Yiu Z, et al. Presented at the European Association of Dermatology and Venereology. Berlin, Germany. October 11-14, 2020. Poster D1T01.1K.